Fujifilm Diosynth Biotechnologies is investing $1.2 billion to expand its biopharmaceutical manufacturing facility in Holly Springs, N.C. Fujifilm initially invested $2 billion in the Holly Springs operation in 2021. The company said the investment made it one of North America’s largest end-to-end biopharmaceutical manufacturing facilities. The new expansion will create 680 new jobs in the…
Fujifilm establishing cell culture subsidiary in Korea
Fujifilm announced today that it is establishing a Seoul, South Korea–based subsidiary to accelerate its business growth in the cell culture media space. With paid-in capital of ₩300 million (roughly $250,000), the new subsidiary opens tomorrow. It will import cell culture media for bioproduction and advanced cell and gene therapies. Its goal through its direct…
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
The multinational conglomerate Fujifilm will invest $1.6 billion to improve and ramp up the cell culture manufacturing services of its CDMO subsidiary Fujifilm Diosynth Biotechnologies. Most of the investment will focus on a site in Hillerød, Denmark. A site in College Station, Texas, will also benefit from a funding injection. The investment will increase the…
Fujifilm to aquire Atara’s T-cell manufacturing facility in California for $100M
Atara Biotherapeutics announced yesterday that Fujifilm will acquire its T-cell operations and manufacturing (ATOM) facility for $100 million. South San Francisco-based Atara entered into a long-term strategic agreement with Fujifilm’s Diosynth Biotechnologies (FDB) subsidiary under which Fujifilm will acquire the ATOM facility in Thousand Oaks, Calif., and retain current manufacturing and quality staff at the…
Fujifilm to expand vaccine production plant in England
Fujifilm (TSE:4901) is spending big to double the size of its United Kingdom-based vaccine manufacturing facility. According to a news release, Fujifilm is spending about $532.8 million (£400 million) to expand its Teesside (north-east England) plant making the Novavax COVID-19 vaccine. The expansion includes facilities specializing in antibody treatments and viral gene therapies. Fujifilm said…
Fujifilm Diosynth lands $265m to produce COVID-19 vaccine
Fujifilm Diosynth Biotechnologies announced that its College Station, Texas, site will manufacture a COVID-19 vaccine candidate under a $265 million federal contract. The contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies said it received the federal task order through the Texas A&M System Center for Innovation in Advanced Development &…